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Abstract It has previously been demonstrated that the unnatural 
amino acid p-Cl-phenylalanine can be attached to tRNA ehe by a 
modified phenylalanyl-tRNA syntbetase with relaxed amino acid 
substrate specificity. We show that this modification to the trans- 
lational machinery of Escherichia coil is the only requirement for 
the incorporation of either p-Cl- or p-Br-phenylalanine into full- 
length luciferase in vitro. The incorporation ofp-Cl-phenylalanine 
was also demonstrated in vivo using a suitably modified host 
strain. These results represent he first description of the incorpo- 
ration into a protein in vivo of an unnatural amino acid which is 
normally rejected by the cellular translational machinery. 
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tRNA phe [10]. It was also shown that p-Cl-Phe is taken up by 
E, coli and that it can be toxic to cells producing A294G PheRS 
[10,11], although it was not clear whether this resulted from 
incorporation of the unnatural amino acid into proteins or 
depletion of the cellular tRNA Phe pool. In the work reported 
here we have investigated whether p-Cl-Phe and a second un- 
natural amino acid, p-Br-Phe, are incorporated into a target 
protein and if this incorporation affects the overall efficiency 
of translation. The choice of American firefly (Photinus pyralis) 
luciferase as the target protein, which contains 29 phenylalan- 
ine codons [12], also enabled us to readily assess any effects of 
unnatural amino acid incorporation on enzymatic activity. 
2. Materials and methods 
I. Introduction 
A number of methods have recently been developed which 
expand the use of site-directed mutagenesis to allow the site- 
specific incorporation of unnatural amino acids in vitro [1,2,3]. 
The success of such techniques has demonstrated the ability of 
the translation machinery to recognise a wide range of non- 
cognate aminoacylated tRNAs in vitro. Over the same period 
it has also become clear that the non-cognate pairing tRNA C~n- 
Glu, which is found in mitochondria, chloroplasts and some 
eubacteria, is excluded from the process of translation [4,5]. In 
this work we set out to investigate whether other non-cognate 
pairings would also be excluded in vivo and if they were not, 
how they would affect the synthesis and activity of a heterolo- 
gous target protein. As it has previously been demonstrated 
that amino acid analogues ufficiently similar to their natural 
counterparts are both aminoacylated and incorporated into 
proteins (reviewed in [6]) we chose unnatural amino acids which 
are not normally substrates for any of the aminoacyl-tRNA 
synthetases. 
The function of the aminoacyl-tRNA synthetases i  to cat- 
alyse the attachment of amino acids to their cognate tRNAs 
(for reviews see [7,8]), a process whose fidelity is maintained 
both at the level of substrate discrimination and proofreading 
of non-cognate intermediates and products [9]. It has previ- 
ously been shown that replacement of Ala-294 by Gly in Esch- 
erichia coli phenylalanyl-tRNA synthetase (PheRS I) ~ subunits 
results in the normally non-cognate amino acid, p-Cl-phenyl- 
alanine (p-C1-Phe), becoming a substrate for attachment to 
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2.1. Bacterial strains and plasmids 
All in vivo labelling experiments were performed using the E. coli 
strains KA3 (pheSA294G) and KA4 which are isogenic except for the 
pheS allele [10]. KA3 produces PheRS containing wild-type fl subunits 
and mutant c~ subunits with the A294G replacement whereas KA4 
produces wild-type PheRS. The plasmid pBESTluc (Promega, Madi- 
son, W1) was used as the source of the American firefly luciferase gene. 
DNA templates for in vitro coupled transcription/translation werepre- 
pared from E. coli strain HB101 previously transformed with 
pBESTluc. In order to allow the regulation of in vivo synthesis of 
luciferase in strains KA3 and KA4, they were co-transformed with 
pBEST/uc and pET24a (Invitrogen, San Diego, CA). 
2.2. Reagents 
p-Bromo-L-phenylalanine was from Fluka Chemic AG (Buchs, Swit- 
zerland), p-chloro-D,L-phenylalanine from Sigma (St. Louis, MO), p- 
chloro-D,L-[1-~4C]phenylalanine d translation grade [35S]methionine 
from NEN-DuPont (Boston, MA) and L-[U-~4C]phenylalanine from 
Amersham International (Amersham, UK). Firefly luciferase from 
Photinus pyralis was obtained from Boehringer (Mannheim, Germany), 
while GroEL, GroES, DnaK, DnaJ, and GrpE were all from StressGen 
(Victoria, B.C., Canada). Wild-type and A294G PheRS were purified 
as previously described [10]. Anti-luciferase antibodies were from 
Promega (Madison, WI), anti-GroEL antibodies from Epicentre Tech- 
nologies (Madison, WI) and anti-DnaK antibodies were kindly pro- 
vided by Dr. B. Bukau (Zentrum ftir Molekulare Biologic, Universit~it 
Heidelberg, Germany). 
2.3, In vitro transcription~translation 
Cellular extracts ($30) for coupled transcription/translation were 
prepared either from Salmonella typhimurium strain SK419 as described 
previously [13] or from E. coli SL119 (obtained from Promega, Madi- 
son, WI). While both extracts howed comparable vels of luciferase 
synthesis, the E. coli extract gave significantly higher background and 
hence the S. typhimurium extract was used in all experiments described. 
Reactions were performed essentially as described [14] except hat the 
amino acid composition was altered and additional enzymes included 
as indicated for particular experiments. Protein was prepared for poly- 
acrylamide gel electrophoresis (PAGE) as described [14]. DNA tem- 
plates were prepared from overnight cultures of E. coli HB101/ 
pBEST/uc grown on LB medium containing 25/.tg/ml ampicillin. Plas- 
mids were isolated using Qiagen plasmid kits (Qiagen Inc., Chatsworth, 
CA) followed by linearization with Xhol restriction enzyme. Linearized 
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templates were then extracted with phenol and methylene chloride and 
finally resuspended in TE buffer at a final concentration of approxi- 
mately 0.5 ¢tg//~l. 1.5/lg template was then used in a final reaction 
volume of 50/11. 
2.4. Visualisation of radiolabelled proteins 
35S-Labelled proteins were visualised using a Molecular Dynamics SF 
Phosphorimager. 14C-Labelled proteins were visualised as follows. Poly- 
acrylamide gels were treated for 30 min in each of the following: 45% 
ethanol/5% acetic acid/2% glycerol, then water, then 1 M sodium sali- 
cylate. Gels were dried at 60°C and exposed to X-ray film at minus 
80°C for 2-6 weeks. 
2.5. Immunoblots 
Proteins were separated by SDS-PAGE and electroblotted onto ni- 
trocellulose filters as described [15]. Proteins cross-reacting with the 
appropriate antibodies were detected by chemiluminescence using a 
Western Blotting Kit from Boehringer (Mannheim, Germany). 
2.6. Immunoprecipitation of luciferase 
100,ul Pansorbin cells (Calbiochem, La Jolla, CA) were washed twice 
with 900 ¢tl of 20 mM HEPES, pH 7.5, and finally resuspended in 1 ml 
of the same buffer. 5 ¢tl of anti-luciferase was added and the cells 
incubated with shaking at room temperature for 20 min followed by 
three washes in 900 ~1 of 20 mM HEPES, pH 7.5, 150 mM NaC1, 10% 
glycerol, 0.1% Triton X- 100. Cells were resuspended in 950/11 of 50 mM 
Tris-HC1, pH 8, 150 mM NaCI, 1% Triton X-100, 1 mM phen- 
ylmethanesulfonyl fluoride (PMSF) to which was added either 30/A of 
in vitro translation product or 250 ~l of cell lysate. Cells were incubated 
overnight with shaking at 4°C followed by washing in 900/11 of each 
of buffer 1 (50 mM HEPES, pH 7.5,500 mM NaCI, 0.2% Triton X-100, 
5 mM EDTA), buffer 2 (50 mM HEPES, pH 7.5, 150 mM NaC1, 0.1% 
Triton X-100, 5 mM EDTA, 0.1% SDS) and buffer 3 (10 mM Tris-HC1, 
pH 8, 0.1% Triton X-100). Cells were finally resuspended in 20 ¢tl of 
standard SDS-PAGE loading buffer and incubated at 90°C for 5 min. 
Supernatants were analysed on a 10% polyacrylamide g l. 
2.7. In vivo incorporation of phenylalanine analogues 
A 10-ml culture was grown overnight at 30°C in M9 medium contain- 
ing ampicillin (100 ¢tg/ml) and kanamycin (30 mg/ml) to an absorbance 
at 600 nm (A~oo) in the range of 1-1.5. The culture was centrifuged and 
the cells were re-suspended and diluted in M9 medium containing 
ampicillin (50 ¢tg/ml), kanamycin (30/Jg/mg), tryptophan (1 mM) and 
tyrosine (0.1 mM) to give a final A6o 0 of 0.5. The culture was then grown 
to an A~) in the range 0.74).9 prior to the addition of isopropyl-fl-o- 
thiogalactopyranoside (IPTG) to a final concentration f 1 mM. After 
a further 10 min incubation either p-chloro-o,L-[~4C]phenylalanine or 
[~4C]phenylalanine was added to a final concentration of 600/IM (8.7 
mCi/mmol) of the e-enantiomer. Cultures were then incubated until the 
A~u, reached approximately 1.1. The cells were harvested and lysates 
prepared as described before [16] except hat PMSF was added to the 
lysis buffer at a final concentration of 1 mM. 
2.8. Luciferase activity determinations 
Luciferase activity was assayed in appropriately diluted samples 
using the Luciferase Assay System supplied by Promega (Madison, WI) 
in a scintillation counter with all channels open. 
3. Results 
3. I. In vitro incorporation of  phenylalanine analogues into 
luciferase 
The incorporation ofp-Cl-Phe into luciferase during in vitro 
translation was investigated as follows. $30 extracts were incu- 
bated at 35°C for 2 h with template DNA,  premix lacking 
phenylalanine, p-Cl-[14C]Phe (1 mM) and PheRS (0.2 mM). 30 
ml aliquots were then removed and immunoprecipitated with 
anti-luciferase prior to SDS-PAGE and visualisation (Fig. 1). 
Two bands were visible, one corresponding to full-length lucif- 
erase (61 kDa) and the second to a smaller 48 kDa internal 
start-site luciferase (Promega, Madison, WI). The addition of 
exogenous PheRS slightly reduces the overall evel of luciferase 
synthesis and may result from a less favourable interaction 
between S. typhimurium tRNA Phe with E. coli PheRS than with 
S. typhimurium PheRS. As p-Br-[14C]Phe was not available, the 
incorporation of p-Br-Phe was investigated indirectly by 
[35S]methionine labelling. $30 extracts were incubated at 35°C 
for 30 min with template DNA and a premix lacking phenyla- 
lanine but containing low concentrations of unlabelled 
methionine (20 mM) in order to deplete the endogenous phen- 
ylalanine pool prior to the initiation of protein labelling. A 
postmix containing [35S]methionine (10 ¢tCi/ml), phenylalanine, 
p-Br-Phe (1 mM), wild-type or A294G PheRS (0.2 mM), and 
IPTG (1 mM) was then added and the reaction incubated for 
a further 90 min. Samples were analysed by SDS-PAGE fol- 
lowed by phosphorimaging and gave comparable results to 
those described above for p-C1-Phe incorporation (data not 
shown). This data shows that p-Cl- and p-Br-Phe are both 
incorporated into luciferase exclusively in the presence of 
A294G PheRS and this incorporation does not affect the level 
of translation of full-length protein. 
3.2. Enzymatic activity of luciferase containing p-Cl- or 
p-Br-Phe 
In order to compare the enzymatic activity of luciferase con- 
taining Phe and that containing p-C1- or p-Br-Phe, identical 
reactions to those described before were performed except hat 
unlabelled amino acids were used. Samples were removed after 
2 h and the activity assayed as described above. Although 
comparable l vels of luciferase were observed after the incorpo- 
ration ofp-C1-Phe, p-Br-Phe or Phe in the presence of A294G 
PheRS (controlled by immunoblotting, results not shown), the 
incorporation of the unnatural amino acids reduced activity by 
over 99%. 
As it has previously been demonstrated that a complex of the 
AA p-CI-Phe Phe 
PheRS I wt IA294G I wt I A294G 
3) 
Fig. 1. Immunoprecipitation with anti-luciferase immunoglobulins of t4C-labelled in vitro translated luciferase. Reactions were performed as indicated 
in the text. 'AA' refers to the L4C-labelled amino acid and 'PheRS' refers to the purified PheRS protein added to the premix (wt = wild type; 
A294G = A294G PheRS). LUCp refers to the full-length luciferase protein and isLUCp to a truncated internal start-site form (see text for details). 
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LUCp (61kDa)-> 
isLUCp (48kDa)-> 
Fig. 2. In vivo labelling of luciferase with p-Cl-[14C]Phe. E coli strains 
KA3 (which produces A294G PheRS) and KA4 (which produces wild- 
type PheRS) were used for p-Cl-[~4C]Phe labelling of luciferase as indi- 
cated in the text. Samples of cell lysates were then used for both im- 
munoprecipitation and immunoblotting with anti-luciferase. Panel A 
is an autoradiograph of immunoprecipitated luciferase, while panel B 
is an immunoblot. LUCp refers to the full-length luciferase protein and 
isLUCp to a truncated internal start site form (see text for details). It
is worth noting that the ratio of full-length to truncated luciferase is
considerably higher in vivo than in vitro. 
both strains, p-C1-Phe was only incorporated into luciferase by 
strain KA3. This was confirmed by assaying the enzymatic 
activity in the lysates which was 75% lower in KA3 than in KA4 
in agreement with the in vitro results which also showed a 
reduction in activity uponp-C1-Phe incorporation. The residual 
25% activity can be explained by the production of luciferase 
prior to the addition of p-C1-Phe and the presence of en- 
dogenous Phe in the cells. 
The effect of luciferase xpression and the incorporation of
p-Cl-Phe into cellular proteins on chaperone l vels was also 
investigated by immunoblotting. Comparison of the changes 
with and without IPTG and p-Cl-Phe addition indicates that 
while luciferase production results in increased levels of DnaK, 
but not GroEL, the incorporation ofp-C1-Phe does not lead to 
any additional changes in chaperone l vels (data not shown). 
4. Discussion 
chaperones DnaK, DnaJ and GrpE is able to restore the enzy- 
matic activity of thermally deactivated luciferase [17], the incor- 
poration reactions for p-C1-Phe and Phe were repeated with the 
addition of various chaperones. In all cases the addition of 
chaperones did not alter activity (Table 1). As a control of 
chaperone activity, samples were also removed at the end of the 
reactions, diluted into luciferase renaturation buffer [17] con- 
taining chaperones and ATE heat treated for 10 min at 42°C 
(inactivation period) and then incubated for 90 min at room 
temperature (recovery period). While all samples were inactive 
following heat reatment, partial restoration ofenzymatic activ- 
ity was only observed in proteins which did not contain p-Cl- 
Phe (Table 1). 
3.3. In vivo incorporation of p-Cl-Phe into luciJerase 
The incorporation of p-Cl-Phe into luciferase in vivo was 
investigated using the E. coli strains KA3, which contains the 
chromosomal pheSA294 mutation, and KA4, which contains 
the wild-typepheS gene. Both strains were transformed with the 
plasmids pBESTIue and pET24a in order to allow IPTG-induc- 
ible luciferase xpression. Luciferase xpression, p-C1-Phe la- 
belling and cell lysate preparation were performed with both 
strains as described above. Aliquots from the cell lysates were 
used for both immunoprecipitation and immunoblotting (Fig. 
2). While comparable amounts of luciferase were produced in 
4.1. Incorporation of p-Cl-Phe and p-Br-Phe into luciferase 
The incorporation ofp-Cl- and p-Br-Phe into luciferase dur- 
ing in vitro translation of the luciferase gene is clearly shown 
in Fig. 1. The only modification required to a standard $30 
extract o achieve this was the addition of A294G PheRS to 
catalyze the attachment of the unnatural amino acid to 
tRNA Phe. This was confirmed in vivo by expressing luciferase 
in the presence of p-Cl-Phe using an E. coli strain containing 
the pheSA294G mutation (Fig. 2). These results indicate that 
the only barrier to the incorporation ofp-C1-Phe into cellular 
proteins is at the level of substrate discrimination by PheRS. 
There is apparently no discrimination by elongation factor Tu, 
whose function is to correctly present aminoacyl-tRNAs tothe 
ribosome for mRNA decoding [18], or by the ribosomal A site, 
a phenomenon previously demonstrated fora number of unnat- 
ural amino acids [19,20]. The production of comparable vels 
of predominantly full-length luciferase with or without p-Cl- 
Phe incorporation i dicates that no exclusion occurs and that, 
additionally, the unnatural amino acid does not cause early 
termination of translation. Similar observations have previ- 
ously been made for the incorporation ofamino acid analogues 
such as azaleucine [21] and furanomycin [22], both of which are 
substrates of wild-type aminoacyl-tRNA synthetases. By con- 
trast, the results described here represent the first description 
of the incorporation i to a protein in vivo of an unnatural 
amino acid which is normally excluded from the translation 
machinery of E. coli by virtue of its chemical structure. 
Table 1 
The effect of chaperones on luciferase activity during in vitro translation and on the reactivation ofthermally inactivated luciferase 
Amino acid added Chaperones" Relative luciferase activity (%) 
Translation product b After inactivation and renaturation c 
p-CI-Phe GroEL/GroES 0.12 0 
p-CI-Phe DnaK/DnaJ/GrpE 0.17 0 
p -C1-Phe  DnaKIDnaJ/GrpE/GrELIGroES 0.09 0 
p-C1-Phe - 0.08 0 
Phe GroEL/GroES 93 5.8 
Phe DnaK/DnaJ/GrpE 100 10 
Phe DnaK/DnaJIGrpE/GrEL/GroES 86 9.5 
Phe 94 0 
For both the translation and reactivation reactions chaperones were added in the ratio luciferase : DnaK : DnaJ : GrpE : (GroEL)~: (GroES)7 
1:5:2:5:1:1 as previously described [21]. ATP was added at a final concentration f 1 mM. 
ball in vitro translation reactions were performed as for the reactions in Fig. 1 except that A294G PheRS (0.2 mM) was present in all cases. 
c All samples had zero activity after heat inactivation. 
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4.2. Characterization of luciferase containing p-Cl-Phe 
While p-C1-Phe ssentially acts as a homologue of Phe during 
translation i  the presence of A294G PheRS, the incorporation 
of the unnatural amino acid dramatically reduces enzymatic 
activity both in vitro and in vivo. The likely explanation is that 
the replacement of Phe by p-C1-Phe disrupts a hydrophobic 
core structure in luciferase, which would in turn be expected to 
destabilize the protein [23]. This is supported by the work of 
Kajiyama and Nakano [16] on the thermostability of Luciola 
cruciata luciferase, which shares 67% amino acid sequence ho- 
mology with American firefly luciferase [24]. They showed that 
the thermostability of a series of single amino acid substitutions 
correlated with the hydrophobicity of the substituted residue. 
Given that p-C1-Phe could be expected to substitute for phen- 
ylalanine at a number of positions, it was not surprising that 
this caused significant structural disruption and consequently 
abolished activity. 
Luciferase has previously been shown to form productive 
folding interactions with the chaperone complex DnaK/DnaJ/  
GrpE [17], as was confirmed here by the reactivation of wild- 
type luciferase following heat inactivation (Table 1). Some reac- 
tivation of wild-type protein was also observed in the presence 
of GroEL/GroES, in agreement with the observation that the 
eukaryotic GroEL homologue TRiC can interact with lucif- 
erase during folding [25]. Neither of the chaperone complexes 
had any effect on the enzymatic activity ofp-C1-Phe-containing 
luciferase, regardless of whether they were added before pol- 
ypeptide chain synthesis or prior to deactivation of full-length 
protein. In vivo, the expression of luciferase led to an increase 
in the levels of both DnaK and to a lesser extent GroEL, but 
no additional effect was observed when p-C1-Phe was incorpo- 
rated. Similarly, the addition ofp-Cl-Phe to strain KA3 without 
the induction of luciferase xpression had no detectable ffect 
on chaperone levels. Taken together the in vivo and in vitro 
results suggest hat p-C1-Phe-containing luciferase ither is not 
recognised as a substrate by these chaperones or is recognised 
but cannot be folded to an active form. 
4.3. Future prospects 
The results described emonstrate hat an unnatural amino 
acid can be incorporated into proteins in vivo as a direct result 
of a modification in the substrate specificity of an aminoacyl- 
tRNA synthetase. The data also highlights the need to further 
refine such a system to allow site-specific replacements which 
would be expected to be less disruptive to the structure and 
activity of target proteins. It can be envisaged that this could 
be achieved through two additional modifications to the sub- 
strate specificity of PheRS, a wild-type copy of which would 
also have to be present o ensure continued Phe incorporation. 
First, Phe itself would have to be excluded as a substrate and 
second, the mutant PheRS would have to show an increased 
affinity for a nonsense suppressor tRNA phe compared with the 
wild-type. Such a mutant PheRS would then allow the site- 
specific incorporation of p-C1-Phe at codons mutated to the 
appropriate termination codon [6]. 
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